Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin
Eileen M Moore, Alastair G Mander, David Ames, Mark A Kotowicz, Ross P Carne, Henry Brodaty, Michael Woodward, Karyn Boundy, Kathryn A Ellis, Ashley I Bush, Noel G Faux, Ralph Martins, Cassandra Szoeke, Christopher Rowe, David A Watters
Diabetes Care | AMER DIABETES ASSOC | Published : 2013
Related Projects (1)
The PRIME study was funded by Janssen Australia.This study received support from the National Health and Medical Research Council via the Dementia Collaborative Research Centres program (DCRC2). The AIBL study currently receives funding from the Science Industry Endowment fund.Pfizer International contributed financial support to assist with analysis of blood samples and to further the AIBL research program. Core funding for the AIBL study was provided by the Commonwealth Scientific and Industrial Research Organisation (CSIRO), which was supplemented by in-kind contributions from the study partners: The University of Melbourne, Neurosciences Australia Ltd., Edith Cowan University, Mental Health Research Institute, Alzheimer's Australia, National Ageing Research Institute, Austin Health, University of Western Australia, CogState Ltd., Macquarie University, Hollywood Private Hospital, and Sir Charles Gardner Hospital.AIBL is a shareholder in Cogstate Ltd., Prana Biotechnology Ltd., Mesoblast Pty Ltd., and Eucalyptus Pty Ltd. A.I.B. is a former consultant for Prana Biotechnology Ltd., has received speaker fees from Amgen, and is supported by an Australia Fellowship from the National Health and Medical Research Council (NHMRC). N.G.F. is supported by an NHMRC training fellowship. C.S. is supported in part by a research fellowship funded by Alzheimer's Australia. No other potential conflicts of interest relevant to this article were reported.